Mingjuan Hou is the vice president of Qualcomm. In her role, she leads and manages Qualcomm’s brand strategy, corporate communications, product marketing, digital communications, and media/industry analyst relations in China, and providing communications consel to senior management.
Mingjuan has more than 20 years of rich experience in corporate communications, branding, marketing strategy, digital communications, crisis management and public affairs. Since joining Qualcomm in 2002, she led the team successfully executing multiple branding and marketing campaigns and spearheaded long-term strategic collaborations with renowned IPs such as China National Geography and the KPL. These initiatives have significantly broadened and deepened the presence of Qualcomm’s corporate brand — as well as its product brands, Snapdragon® and Qualcomm Dragonwing™ — across more diverse, consumer-relevant touchpoints, which greatly enhance their awareness and reputation in the Chinese market. She led to establish Qualcomm’s corporate communications strategy and social media platforms in China, and helped develop co-marketing strategy with leading Chinese smart device makers, auto companies, e-commerce platforms, IoT vendors and many more. In addition, She is also a long-standing advocate for advancing women in technology. Leveraging her own career journey and Qualcomm’s best practices, she actively champions the empowerment of women and supports their continued growth, impact, and leadership across the tech industry.
Mingjuan is a recipient of a number of industry and corporate leadership awards, including AmCham China’s Outstanding Female Leader Award (2026), Xinhuanet’s Mulan Yue Xianghui Empowerment Award (2024),Forbes China’s Top 100 Businesswomen (2023), Fortune China’s Most Influential Businesswomen (2021), Cyzone’s Most Notable Businesswomen (2020) and Communications World’s Best 5G Practitioner (2020).

Aggie Liu is a partner leading China intellectual property practice at Baker McKenzie FenXun. She provides advice covering a full range of intellectual property-related services, including enforcement, litigation, domain name disputes, copyright and designs, digital content, advertising compliance, IP licensing and transactions, and other intellectual property matters. Aggie regularly represents clients in trademark, copyright, trade secret, unfair competition, and patent disputes. Her experience spans all stages of dispute resolution, from developing litigation strategies and obtaining pre-trial relief (including evidence preservation, asset preservation, and preliminary injunctions) to trial proceedings and enforcement of court judgments. She also has extensive experience in IP portfolio management and the commercialization of intellectual property assets.

In addition, Aggie frequently advises multinational and domestic companies on advertising and marketing compliance matters, including compliance reviews of advertising campaigns, promotional activities, influencer and social media marketing, product claims, comparative advertising, endorsement and sponsorship arrangements, and consumer protection issues.

Hao Meng is an Associate at FenXun Partners. He advises clients on a broad range of intellectual property matters, including IP enforcement and litigation, domain name disputes, copyright and design protection, digital content, advertising, IP licensing and transactions, and related commercial issues. His experience covers all stages of contentious matters, including litigation strategy development, pre-trial remedies, court proceedings, and judgment enforcement. He also has substantial experience in IP portfolio management, intellectual property commercialization, and traditional dispute resolution.

Hao also advises clients on advertising, marketing, and commercial compliance matters. He has experience conducting advertising law reviews for marketing materials, promotional campaigns, online content, and product claims, as well as advising on social media and influencer marketing, consumer protection, unfair competition, and regulatory compliance issues.